Thermo Trauma Port

After impressing the Anglia Capital Group investment committee, TTP were presented to the group’s investors in September 2024. The group were particularly impressed with:

​

• The critical problem the device solves in trauma care.

• Data from early-stage trials demonstrating the device's effectiveness.

• A well-researched pathway to regulatory approval and widespread market adoption.

• Well-developed relationships with potential customers.

• Clear financial projections and scalability strategies.

• ​

Three angel investors from the group went on to invest as part of a £250,000 SEIS-eligible round. These investors bring with them a wealth of expertise in medtech, wider business and investing experience; they could clearly see the potential for this product to be used worldwide.

​

This pivotal early-stage funding will allow TTP to:

​

• Accelerate product development, including further clinical trials and necessary certifications.

• Scale production through partnerships with contract manufacturers.

• Expand its marketing efforts to raise awareness amongst key potential customers.

​

​

​​“As a regionally focussed angel investment network, we are delighted to see a Norfolk-based start-up working with customers across the globe. This investment will allow Thermo Trauma Port to move ahead with their ambitious plans for growth. Our members are looking forward to being a part of this company’s journey as they work towards transforming outcomes for critically ill patients”

 

Laura Hood, Operations Director, Anglia Capital Group.

​

About Thermo Trauma Port

​

Founder, Inventor and CEO, Mary Anne Cordeiro leads a team of collaborators including product design and manufacturing specialist, MJS Healthcare, East Anglian Air Ambulance (EAAA) and University Hospital of Birmingham. She commented:

​

“The team has been working on TTP for the past seven years including all aspects of product development, funding applications and investor pitches, usability studies, design for manufacture, production scale-up as well as regulatory submissions and IP protection. We have already patented the device in US and Europe, which has several innovative features and are about to embark on launch of the device in the US for military customers. Other potential users include A&E hospitals, air and road ambulances, ski patrol and mountain rescue medical teams as well as emergency and disaster relief services.”

 

The company’s mission is to transform the management of trauma and critically ill patients resulting in safer, easier and more secure transfers by medics and paramedics.

 

Dr Jeremy Mauger, Pre-hospital Consultant at EAAA and TTP co-inventor explains:

 

“The impetus for this development came from us clinicians at EAAA who were keen to find a solution to prevent trauma patients having to be moved multiple times which risks the potential of further injury. We have also experienced many patients exhibiting loss of body heat in trauma situations. Patients can also lose further body heat when being transferred from the scoop stretcher to other ambulance trolleys and hospital beds. Unfortunately, hypothermia is common in trauma victims and can reduce chances of survival.”

 

Rigorous research on the values of healthcare specialists involved in transporting patients by air and/or road identified the following problems:

​

• Patients are manually handled many times which risks further injury

• Patients lie on cold and hard transfer devices which risks reduced body temperature and increased pressure sore development

• Re-use of emergency transfer devices which risks cross infection and increased staff downtime

• ​

How TTP addresses these challenges:

​

• Patient stays on device throughout the journey, pre- and in-hospital including diagnostic imaging (CT scan)

• Patient is kept warm and comfortable with smart alert to ensure temperature is controlled in an acceptable range

• Single-use disposable cover to prevent cross-infection risk between patients

 

 

 

 

​